These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 29117353)

  • 1. Quantifying Overdiagnosis in Cancer Screening: A Systematic Review to Evaluate the Methodology.
    Ripping TM; Ten Haaf K; Verbeek ALM; van Ravesteyn NT; Broeders MJM
    J Natl Cancer Inst; 2017 Oct; 109(10):. PubMed ID: 29117353
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Conditions for Valid Empirical Estimates of Cancer Overdiagnosis in Randomized Trials and Population Studies.
    Gulati R; Feuer EJ; Etzioni R
    Am J Epidemiol; 2016 Jul; 184(2):140-7. PubMed ID: 27358266
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Discrepancies and overdiagnosis in breast cancer organized screening. A "methodology" systematic review].
    Gocko X; Leclerq M; Plotton C
    Rev Epidemiol Sante Publique; 2018 Nov; 66(6):395-403. PubMed ID: 30316554
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Extrapolation of pre-screening trends: Impact of assumptions on overdiagnosis estimates by mammographic screening.
    Ripping TM; Verbeek AL; Ten Haaf K; van Ravesteyn NT; Broeders MJ
    Cancer Epidemiol; 2016 Jun; 42():147-53. PubMed ID: 27153471
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Missteps in Current Estimates of Cancer Overdiagnosis.
    Lee CI; Etzioni R
    Acad Radiol; 2017 Feb; 24(2):226-229. PubMed ID: 27894707
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Overdiagnosis in the population-based organized breast cancer screening program estimated by a non-homogeneous multi-state model: a cohort study using individual data with long-term follow-up.
    Wu WY; Törnberg S; Elfström KM; Liu X; Nyström L; Jonsson H
    Breast Cancer Res; 2018 Dec; 20(1):153. PubMed ID: 30558679
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Estimation of overdiagnosis in breast cancer screening using a non-homogeneous multi-state model: A simulation study.
    Wu WY; Nyström L; Jonsson H
    J Med Screen; 2018 Dec; 25(4):183-190. PubMed ID: 29153013
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Recognizing the Limitations of Cancer Overdiagnosis Studies: A First Step Towards Overcoming Them.
    Etzioni R; Gulati R
    J Natl Cancer Inst; 2016 Mar; 108(3):. PubMed ID: 26582245
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Quantifying and monitoring overdiagnosis in cancer screening: a systematic review of methods.
    Carter JL; Coletti RJ; Harris RP
    BMJ; 2015 Jan; 350():g7773. PubMed ID: 25569206
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Mammography screening: A major issue in medicine.
    Autier P; Boniol M
    Eur J Cancer; 2018 Feb; 90():34-62. PubMed ID: 29272783
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Breast, prostate, and thyroid cancer screening tests and overdiagnosis.
    Jung M
    Curr Probl Cancer; 2017; 41(1):71-79. PubMed ID: 28104314
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Obligate Overdiagnosis Due to Mammographic Screening: A Direct Estimate for U.S. Women.
    Hendrick RE
    Radiology; 2018 May; 287(2):391-397. PubMed ID: 29267146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Overdiagnosis in breast cancer screening: The impact of study design and calculations.
    Lynge E; Beau AB; Christiansen P; von Euler-Chelpin M; Kroman N; Njor S; Vejborg I
    Eur J Cancer; 2017 Jul; 80():26-29. PubMed ID: 28535494
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lifetime risk of prostate cancer overdiagnosis in Australia: quantifying the risk of overdiagnosis associated with prostate cancer screening in Australia using a novel lifetime risk approach.
    Pathirana T; Hayen A; Doust J; Glasziou P; Bell K
    BMJ Open; 2019 Mar; 9(3):e022457. PubMed ID: 30858156
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Overdiagnosis associated with breast cancer screening: A simulation study to compare lead-time adjustment methods.
    Seigneurin A; Labarère J; Duffy SW; Colonna M
    Cancer Epidemiol; 2015 Dec; 39(6):1128-35. PubMed ID: 26341587
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimation of overdiagnosis using short-term trends and lead time estimates uncontaminated by overdiagnosed cases: Results from the Norwegian Breast Screening Programme.
    Michalopoulos D; Duffy SW
    J Med Screen; 2016 Dec; 23(4):192-202. PubMed ID: 26940963
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Overdiagnosis in mammography screening for breast cancer].
    Huang YB; Yang L; Song FJ; Chen KX
    Zhonghua Liu Xing Bing Xue Za Zhi; 2017 Nov; 38(11):1574-1578. PubMed ID: 29141352
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Overdiagnosis in cancer screening].
    Cervera Deval J; Sentís Crivillé M; Zulueta JJ
    Radiologia; 2015; 57(3):188-92. PubMed ID: 25174786
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Defining, Estimating, and Communicating Overdiagnosis in Cancer Screening.
    Davies L; Petitti DB; Martin L; Woo M; Lin JS
    Ann Intern Med; 2018 Jul; 169(1):36-43. PubMed ID: 29946705
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Influence of study features and methods on overdiagnosis estimates in breast and prostate cancer screening.
    Etzioni R; Gulati R; Mallinger L; Mandelblatt J
    Ann Intern Med; 2013 Jun; 158(11):831-8. PubMed ID: 23732716
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.